Figures S1-S9 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
Year: 2023
Type: other
Abstract: Supplementary Figure S1: Representative flow strategies for detection of apoptotic cells. Supplementary Figure S2: The top 20 candidates with the highest comboscores from the ORF screen. Supplementary Figure S3: MEX3B expression is higher in non-responders than in responders to anti-PD-1 immunotherapy Supplementary Figure S4: Knockdown of MEX3B increases the susceptibility of tumor cells to T cell-mediated cytotoxicity Supplementary Figure S5: Overexpression of HLA-A2 in 2549 melanoma cells results in similar IFNɣ release in MART-1-specific TILs incubated with melanoma cells overexpressing GFP-MEX3B or GFP control Supplementary Figure S6: Overexpression of MEX3B in 2549 melanoma cells decreases surface HLA-A31 expression Supplementary Figure S7: Overexpression of MEX3B in 2549 melanoma cells does not alter HLA-B or HLA-C expression Supplementary Figure S8: Alteration of expression of antigen processing and presentation machinery components upon MEX3B overexpression Supplementary Figure S9: A schematic graph representing transcription factors that may regulate MEX3B expression.
Authors: Lu Huang, Shruti Malu, Jodi A. McKenzie, Miles C. Andrews, Amjad H. Talukder, Trang Tieu, Tatiana Karpinets, Cara Haymaker, Marie-Andrée Forget, Leila J. Williams, Zhe Wang, Rina M. Mbofung, Zhi-Qiang Wang, Richard Eric Davis, Roger S. Lo, Jennifer A. Wargo, Michael A. Davies, Chantale Bernatchez, Timothy Heffernan, Rodabe N. Amaria, Anil Korkut, Weiyi Peng, Jason Roszik, Gregory Lizée, Scott E. Woodman, Patrick Hwu
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361886034